Blood glucose-lowering activity of a hyaluronan-insulin complex after oral administration to rats with diabetes

Diabetes Technology and Therapeutics

Volumn 7, Issue 6, 2005, Pages 948-957

  Jederström, Gustaf ^a,b   Gråsjö, Johan ^a   Nordin, Astrid ^a   Sjöholm, Ingvar ^a   Andersson, Arne ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HYALURONAN PLUS INSULIN; HYALURONIC ACID; INSULIN DERIVATIVE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; GLUCOSE BLOOD LEVEL; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYALURONIC ACID; INJECTIONS, SUBCUTANEOUS; INSULIN; LINEAR MODELS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 31144434901     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2005.7.948     Document Type: Article

References (27)

1. Pillai O, Panchagnula R: Insulin therapies-past, present and future. Drug Discov Today 2001;6:1056-1061.
2. Cefalu WT: Concept, strategies and feasibility of non-invasive insulin delivery. Diabetes Care 2004;27:239-246.
3. Still JG: Development of oral insulin: progress and current status. Diabetes Metab Res Rev 2002;1(Suppl 1):29-37.
4. Owens DR: New horizons-alternative routes for insulin therapy. Nat Rev Drug Discov 2002;1:529-540.
5. Rave K, Heinemann L, Gonzales C, Ernest CS, Chien J, Muchmore D: Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. Diabet Med 2004;21:763-772.
6. Royle P, Waugh N, McAuley L, McIntyre L, Thomas S: Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2004;3:CD003890.
7. Arbit E: The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004;6:510-517.
8. Kidron M, Dinh S, Menachem Y, Abbas R, Variano B, Goldberg M, Arbit E, Bar-On H: A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med 2004;21:354-357.
9. Arbit E, Nosek L, Kapitza C, Beckett P, Gelfand R, Goldberg M, Heise T: Oral insulin as first-line therapy in type-2 diabetes: a randomized-controlled pilot study [abstract]. Diabetologia 2004;47(Suppl 1):A5.
10. α-deoxycholyl-L-lysyl-methyl ester, for enhancing insulin absorption in the intestine. Diabetologia 2005;48:405-411.
11. Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G: Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 2003;26:421-426.
12. Clement S, Dandona P, Still JG, Kosutic G: Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a Phase I/II clinical trial. Metabolism 2004;53:54-58.
13. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chatturvedi P, Santos CA, Vijayaraghavan K, Montgomery S, Bassett M, Morrell C: Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997;386:410-414.
14. Carino GP, Jacob JS, Mathiowiz E: Nanosphere based oral insulin delivery. J Control Rel 2000;65:261-269.
15. Jederström G, Andersson A, Gråsjo̊ J, Sjöholm I: Formulating insulin for oral administration: preparation of hyaluronan-insulin complex. Pharm Res 2004;21:2040-2047.
16. Honing JB, Sharp K, Yang A-S: Macroscopic models of aqueous solutions and chemical applications. J Phys Chem 1993;97:1101-1109.
17. rd ed. London: Ellis Horwood PTR Prentice Hall, 1993:165-167.
18. th ed. London: Prentice-Hall, 2000:212-215, 241-247, 255-265.
19. SPSS: SPSS Base 7.5 Applications Guide. Chicago: SPSS Inc., 1997:103-119.
20. nd ed. New York: McGraw-Hill, 1992:198-201.
21. Day AJ, Sheehan JK: Hyaluronan: polysaccharide chaos to protein organisation. Curr Opin Struct Biol 2001;11:617-622.
22. Jackson RL, Bush SJ, Cardin AD: Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991;71:481-539.
23. Bendayan M, Ziv E, Gingras D, Ben-Sasson R, Bar-on H, Kidron M: Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia 1994;37:119-126.
24. Sheen-Chen S-H, Ho H-T, Chen W-J, Eng HL, Wu CH: Obstructive jaundice alters CD44 expression in rat small intestine. Digestion 2002;65:112-117.
25. Underhill C: CD44: the hyaluronan receptor. J Cell Sci 1992;103:293-298.
26. Lesley J, Hascall VC, Tammi M, Hyman R: Hyaluronan binding by cell surface CD44. J Biol Chem 2000;275:26967-26975.
27. Castellot JJ Jr, Wong K, Herman B, Hoover RL, Albertini DF, Wright TC, Caleb BL, Karnovsky MJ: Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 1985;124:13-20.